LGALS9 and hepatocellular carcinoma: Blocking of the TIM-3–Gal-9 signaling pathway reactivates T cell–mediated antitumor immunity as confirmed by the enhanced proliferation of T cells and increased cytokine production in the HCC microenvironment.